P1/2, N=61, Not yet recruiting, Radiopharm Theranostics, Ltd

P1/2, N=69, Terminated, Takeda | Active, not recruiting --> Terminated; Terminated due to limited anti-cancer activity

B7-H3 is expressed on a high proportion of pediatric solid tumors. While enoblituzumab could be safely administered at a weekly dose of 15 mg/kg, no objective tumor responses were observed. Alternative strategies to target B7-H3 in children with relapsed solid tumors should be considered.

P1, N=60, Completed, Xencor, Inc. | Active, not recruiting --> Completed

P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2025 --> Jul 2026

P2, N=31, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026

Overall, our findings highlight the potential of CC-3 for clinical evaluation as a therapeutic option for patients with endometrial cancer.

P2, N=200, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.

 The study highlights IL1B, IL15, CD276, NCR2, and CCL17 as key CRS genes in preinfusion CAR T-cell products. Their dysregulation activity may contribute to the increased inflammation noted in CRS, pointing to a loss of regulatory control. Bringing us closer to better patient outcomes, these findings not only suggest that these genes could serve as valuable biomarkers for predicting CRS but also open the way for the development of more precise treatments such as combining drugs such as enoblituzumab and canakinumab, which might assist in reducing CRS severity and making CAR T-cell therapy safer and more effective, ultimately improving patient lives.

P2, N=31, Active, not recruiting, Memorial Sloan Kettering Cancer Center | N=55 --> 31 | Recruiting --> Active, not recruiting

In orthotopic U-87MG models, tumor uptake of 89Zr-labeled MGD009 reached 18.10 ± 0.87% ID/g at 24 h p.i. Additionally, the liver, spleen, and bone marrow also showed a relatively high radioactivity. These findings provide critical insights into the biodistribution and tumor-targeting of MGD009, supporting its potential clinical application in glioblastoma treatment.

P1/2, N=69, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=182 --> 69 | Trial completion date: Jul 2026 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025